Life Sciences Drug Discovery Cheminformatics Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Drug Discovery Cheminformatics Platforms
1.1 - About Life Sciences Drug Discovery Cheminformatics Platforms sector
Companies in the Life Sciences Drug Discovery Cheminformatics Platforms category provide computational chemistry and data management software that helps small‑molecule R&D teams design, evaluate, and prioritize compounds. Their solutions integrate experimental and in silico data, apply AI/ML models, and automate screening so scientists identify hits faster, reduce bench experimentation, and connect workflows from assay results to structure–activity decisions across discovery stages.
Typical offerings include molecular modeling suites for 3D structure exploration, virtual screening and ligand docking engines, QSAR/SAR modeling with feature engineering, and ADMET prediction services. Vendors provide compound registration and chemical database management, reaction enumeration and library design, visualization and analytics dashboards, and APIs to integrate ELNs, HTS pipelines, and LIMS. Many add workflow orchestration and AI-driven de novo design to streamline hit-to-lead optimization and hypothesis testing.
Primary customers are pharmaceutical R&D organizations, biotech discovery groups, and CROs supporting medicinal chemistry programs. Outcomes include accelerated hit identification and lead optimization, lower assay and synthesis costs through in silico triage, improved data governance and reproducibility across labs, and higher candidate quality via early ADMET risk screening. These platforms also enhance collaboration between computational chemists and bench scientists by unifying models, results, and project context.
2. Buyers in the Life Sciences Drug Discovery Cheminformatics Platforms sector
2.1 Top strategic acquirers of Life Sciences Drug Discovery Cheminformatics Platforms companies
Recursion
HQ: United States
Website
- Description: Provider of a tech-enabled drug discovery platform that unites biology, chemistry, machine learning and supercomputing to generate massive proprietary datasets, run millions of weekly wet-lab experiments and decode biological relationships, accelerating the development of new medicines.
- Key Products:
- Recursion OS: End-to-end platform that automates millions of weekly wet-lab experiments, captures multimodal biological and chemical data, and applies ML to uncover trillions of searchable relationships for target and molecule discovery
- Boltz-2 AI Model: Open-source machine-learning model that simultaneously predicts molecular structure and binding affinity with near-FEP accuracy, delivering over 1,000-fold speed and cost savings for small-molecule screening
- In-house Supercomputing Infrastructure: One of the world’s most powerful supercomputers providing massive computational scale to train large biological models and analyze proprietary datasets for faster hypothesis testing
- Phenom-2 Foundation Model: Large-scale model for cell microscopy data that distills image information to enhance transcriptomics and other downstream analyses, improving biological insight generation.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Drug Discovery Cheminformatics Platforms sector
M&A buyer group 1: AI Drug Discovery
18 companies
View group →
Description: Companies in this category build software platforms that apply machine learning and computational chemistry to accelerate target identification, hit discovery, and lead optimization. Life Sciences AI Drug Discovery Platforms unify experimental and omics data, simulate molecular interactions, and prioritize candidates to reduce cycle times and R&D risk. Buyers use these tools to scale discovery pipelines, improve decision quality, and move promising assets toward preclinical validation more efficiently.
Recursion
- Type: N/A
- Employees: ●●●●●
- Description: Provider of a tech-enabled drug discovery platform that unites biology, chemistry, machine learning and supercomputing to generate massive proprietary datasets, run millions of weekly wet-lab experiments and decode biological relationships, accelerating the development of new medicines.
- Key Products:
- Recursion OS: End-to-end platform that automates millions of weekly wet-lab experiments, captures multimodal biological and chemical data, and applies ML to uncover trillions of searchable relationships for target and molecule discovery
- Boltz-2 AI Model: Open-source machine-learning model that simultaneously predicts molecular structure and binding affinity with near-FEP accuracy, delivering over 1,000-fold speed and cost savings for small-molecule screening
- In-house Supercomputing Infrastructure: One of the world’s most powerful supercomputers providing massive computational scale to train large biological models and analyze proprietary datasets for faster hypothesis testing
- Phenom-2 Foundation Model: Large-scale model for cell microscopy data that distills image information to enhance transcriptomics and other downstream analyses, improving biological insight generation.
🔒
🔒
🔒
View all 18 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Drug Discovery Cheminformatics Platforms sector
3.1 - Buyout funds in the Life Sciences Drug Discovery Cheminformatics Platforms sector
2.2 - Strategic buyer groups for Life Sciences Drug Discovery Cheminformatics Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Drug Discovery Cheminformatics Platforms companies
4.2 - Public trading comparable groups for Life Sciences Drug Discovery Cheminformatics Platforms sector
Valuation benchmark group 1: Biologic Drug Discovery Tools Companies
3 companies
View group →
Description: Companies in this trading comparable group are public providers of biologics-focused discovery tools and platforms. They supply recombinant proteins, antibodies, assay reagents, and custom production plus AI-enabled design services that accelerate preclinical research and therapeutic development. They are grouped as comparables given shared catalog and services revenue models, overlapping pharma and research customers, and biotech tools margin profiles, offering consistent public trading comparables for valuation.
Vazyme Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the design, manufacture, and application of bioactive proteins and compounds. The company focuses on innovative enzyme-based solutions for clinical and molecular diagnostics, among other applications.
- Key Products:
- COVID-19 Solution: Comprehensive assay and diagnostic solutions for COVID-19 testing, including qPCR kits and antibodies
- Molecular Biology Solutions: Offering reagents for PCR, qPCR, and NGS applications, catering to research and diagnostic needs
- Custom Oligos: Providing custom oligonucleotide synthesis services with a focus on high-performance and precision
- Enzyme Technologies: Development and manufacturing of enzyme solutions for diverse biological applications
- Reagent Kits: Producing high-quality reagent kits for DNA and RNA extraction and sequencing.
🔒
🔒
🔒
View all 3 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →